A professional knowledgable of biostatistics and FDA regulation was needed in a lawsuit concerning a female patient who underwent a myomectomy and contracted an unexpected malignant leiomyosarcoma. The virulent sarcoma tumor appeared after the patient had recovered from her operation, which had initially only been meant to remove benign fibroids from her uterus using morcellation. Allegedly, the morcellation instead catalyzed the carcinoma in the patient’s tissue. The rarity of this outcome was striking; the FDA had estimated that only 1 in 498 woman would ever contract an un unexpected leiomyosarcoma in this way, and that only 1 in 532 of those tumors would be malignant. Faced with the conclusion that the procedure might have facilitated this incredibly rare outcome to occur, the woman’s gynecologist was sued for malpractice.
Question(s) For Expert Witness
- 1. Are you able to examine and opine on the FDA prevalence rates for unexpected uterine leiomyosarcoma and uterine sarcoma in a woman with presumed benign fibroids?
Expert Witness Response E-035862
I am very experienced in the biostatistics field, and am a former member of an FDA Special Advisory panel. Having 1 individual in 350 or 1 in 500 is quite common, at least by epidemiology standards. I would need to know the number of similar women at risk before saying that her case is unusual.
Contact this expert witness
Related Posts
After undergoing a standard laparoscopic myomectomy to remove fibroid tissue from her uterus, a woman faced severe ramifications after the procedure helped spread cancer throughout her body. The gynecologist had used a morcellator to divide the tissue into smaller pieces…
A patient with a history of mitral valve valvuloplasty faced complications during a procedure to replace his mitral valve, causing him to allege that his doctors had wrongfully recommended him for the operation. After undergoing an elective laparoscopic mitral valve…
